IN VITRO COMPARATIVE INHIBITORY PROFILES OF SEVERAL CYP2D6 INHIBITORS AND METABOLIC CAPABILITIES OF CYP2D6*1, CYP2D6*2, CYP2D6*10, AND CYP2D6*17 ON TRAMADOL METABOLISM

被引：0
|
作者：
Nahid, N. [1 ]
Kanumuri, S. [1 ]
Sharma, A. [1 ]
Wang, D. [1 ]
Johnson, J. [1 ]
机构：
[1] Univ Florida, Gainesville, FL USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2024年 / 115卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PII-080
引用
收藏
页码：S74 / S75
页数：2
相关论文
共 50 条
  • [1] Is CYP2D6 phenotype predictable from CYP2D6 genotype?
    Kiss, Adam Ferenc
    Toth, Katalin
    Juhasz, Cintia
    Temesvari, Manna
    Paulik, Jozsef
    Hirka, Gabor
    Monostory, Katalin
    [J]. MICROCHEMICAL JOURNAL, 2018, 136 : 209 - 214
  • [2] Assessment of Activity Levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 Genes by Population Pharmacokinetics of Dextromethorphan
    Abduljalil, K.
    Frank, D.
    Gaedigk, A.
    Klaassen, T.
    Tomalik-Scharte, D.
    Jetter, A.
    Jaehde, U.
    Kirchheiner, J.
    Fuhr, U.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 88 (05) : 643 - 651
  • [3] CYP2D6 polymorphism in a Gabonese population:: contribution of the CYP2D6*2 and CYP2D6*17 alleles to the high prevalence of the intermediate metabolic phenotype
    Panserat, S
    Sica, L
    Gérard, N
    Mathieu, H
    Jacqz-Aigrain, E
    Krishnamoorthy, R
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 47 (01) : 121 - 124
  • [4] Response to CYP2D6 substrate antidepressants is predicted by a CYP2D6 composite phenotype based on genotype and comedications with CYP2D6 inhibitors
    Gressier, F.
    Verstuyft, C.
    Hardy, P.
    Becquemont, L.
    Corruble, E.
    [J]. JOURNAL OF NEURAL TRANSMISSION, 2015, 122 (01) : 35 - 42
  • [5] Response to CYP2D6 substrate antidepressants is predicted by a CYP2D6 composite phenotype based on genotype and comedications with CYP2D6 inhibitors
    F. Gressier
    C. Verstuyft
    P. Hardy
    L. Becquemont
    E. Corruble
    [J]. Journal of Neural Transmission, 2015, 122 : 35 - 42
  • [6] CYP2D6 genotypes in a Japanese population:: low frequencies of CYP2D6 gene duplication but high frequency of CYP2D6*10
    Nishida, Y
    Fukuda, T
    Yamamoto, I
    Azuma, J
    [J]. PHARMACOGENETICS, 2000, 10 (06): : 567 - 570
  • [7] Metoclopramide is metabolized by CYP2D6 and is a reversible inhibitor, but not inactivator, of CYP2D6
    Livezey, Mara R.
    Briggs, Erran D.
    Bolles, Amanda K.
    Nagy, Leslie D.
    Fujiwara, Rina
    Furge, Laura Lowe
    [J]. XENOBIOTICA, 2014, 44 (04) : 309 - 319
  • [8] Rapid detection of the CYP2D6*3, CYP2D6*4, and CYP2D6*6 alleles by tetra-primer PCR and of the CYP2D6*5 allele by multiplex long PCR
    Hersberger, M
    Marti-Jaun, J
    Rentsch, K
    Hänseler, E
    [J]. CLINICAL CHEMISTRY, 2000, 46 (08) : 1072 - 1077
  • [9] CYP2D6*36 gene arrangements within the CYP2D6 locus:: Association of CYP2D6*36 with poor metabolizer status
    Gaedigk, A
    Bradford, LD
    Alander, SW
    Leeder, JS
    [J]. DRUG METABOLISM AND DISPOSITION, 2006, 34 (04) : 563 - 569
  • [10] CYP2D6 multiallelism
    Daly, AK
    Steen, VM
    Fairbrother, KS
    Idle, JR
    [J]. CYTOCHROME P450, PT B, 1996, 272 : 199 - 210
12345